MARCHF8 and breast carcinoma: To assess whether CD44 is degraded by MARCH8 and/or contributes to the phenotype of MARCH8 in breast cancer cells, we performed immunoblotting, immunofluorescence (IF) staining, and flow cytometry analysis of CD44 in MARCH8-expressing cells.